Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis

  • Aliment Pharmacol Ther. 2004 Aug 1;20(3):333-8. doi: 10.1111/j.1365-2036.2004.02066.x.
A Russo  1 ,  J E Stevens ,  N Giles ,  G Krause ,  D G O'Donovan ,  M Horowitz ,  K L Jones
Affiliations
  • 1. Department of Medicine, Royal Adelaide Hospital, University of Adelaide, Australia.
PMID: 15274670 DOI: 10.1111/j.1365-2036.2004.02066.x
Abstract

Background: KC 11458, a motilin agonist without Antibiotic properties, accelerates gastric emptying in Animals and healthy humans.

Aim: To evaluate the acute effects of KC 11458 on gastric emptying in diabetic gastroparesis.

Methods: Twenty-nine patients (6 type 1 and 23 type 2) with gastroparesis underwent assessments of: (i) gastric emptying of a solid/liquid meal using scintigraphy, (ii) glycaemic control (blood glucose at 0, 30, 60, 90 and 120 min during the gastric emptying measurement) and (iii) upper gastrointestinal and 'meal-related' symptoms (questionnaire), at baseline and after treatment with KC 11458 in a dose of 8 mg t.d.s., or placebo for 8 days.

Results: KC 11458 had no statistically significant or clinically relevant effect on gastric emptying of either the solid intragastric retention at 100 min (T100) (P = 0.87) or liquid 50% emptying time (T50) (P = 0.17) components of the meal. KC 11458 slightly worsened (P = 0.04) upper gastrointestinal symptoms when compared with placebo. The magnitude of the change in solid gastric emptying correlated with the change in the blood glucose concentration (r = 0.49; P < 0.05).

Conclusions: KC 11458, in a dose of 8 mg t.d.s. for 8 days, does not accelerate gastric emptying in patients with diabetic gastroparesis. The absence of efficacy may relate to an effect of hyperglycaemia.

Products